Immunology blend | Immune stimulation
- Lactobacillus rhamnosus – LR04 (DSM 16605)
- Lactobacillus rhamnosus – LR05 (DSM 19739)
- Lactobacillus plantarum – LP01 (LMG P-21021)
- Lactobacillus plantarum – LP02 (LMG P-21020)
- Bifidobacterium animalis subsp. lactis – BS01 (LMG P-21384)
Characteristics
DAILY DOSAGE IN CLINICAL STUDY
2.5 billion CFU + 2.5 billion CFU + 2.5 billion CFU + 2.5 billion CFU + 5 billion CFU + FOS or GOS
FUNCTIONALITY
Reinforcement of the natural defences • Reduction of the intestinal discomfort • Rebalance of the intestinal microbiota
Scientific support
Human clinical trial
1) Pregliasco F. et al. A New Chance of Preventing Winter Diseases by the Administration of Symbiotic Formulations. Journal of Clinical Gastroenterology, 2008; 42(2): 224-233.
2) Belcaro G. et al. Prevention of flu episodes with colostrum and Bifivir compared with vaccination: an epidemiological, registry study. Panminerva Medica 2010;52:269-75.
In vitro study
Mogna L. et al. Micronized Cells of the Probiotic Strain Bifidobacterium lactis BS01 Activate Monocyte Polarization: A New Approach. J Clin Gastroenterol. 2018;52:S57-S61.
+ Internal data on immune stimulation and anti-pathogen activity available upon request for certain strains
Dermatology blend | Atopic dermatitis
- Bifidobacterium animalis subsp. lactis – BS01 (LMG P-21384)
- Lactobacillus rhamnosus – LR05 (DSM 19739)
Characteristics
DAILY DOSAGE IN CLINICAL STUDY
1 billion
FUNCTIONALITY
Atopic dermatitis
Scientific support
Human clinical trial
Manzotti G. et al. Probiotics as a Novel Adjuvant Approach to Atopic Dermatitis. Journal of Contemporary Immunology (2014) Vol. 1 No. 2 pp. 57-66.
+ Immunomodulation in vitro data available upon request
